TaiGen Biopharmaceuticals Holdings Ltd 2024 Annual Report with Sustainability Disclosures
Company: TaiGen Biopharmaceuticals Holdings Ltd
Sector: Manufacturing
Country: Taiwan
Year: 2024
Type: Annual Report with Sustainability Disclosures
Pages: 148
The report highlights TaiGen's 2024 progress on Pixavir marboxil (TG-1000), including successful Phase III results and a China NDA submission, alongside the launch of its first health supplement. The company reported total 2024 revenue of NT$150,651 thousand. It also disclosed a greenhouse gas reduction goal of more than 1% over three years beginning in 2025.
Services
From bulk PDFs to structured indicators and machine-readable documents.